VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$4.75 USD
+0.05 (1.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.77 +0.02 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Earnings News For VTGN
-
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
-
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
-
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
-
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
-
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
-
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
-
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
-
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
-
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
-
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
-
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
-
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
-
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
-
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates
-
Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline
-
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates
-
Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know
-
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
-
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates